Answers are grounded in this paper and cite their sources.
DTC staging is evolving. The pathogenesis of the compromised survival of older patients with DTC is complex, multifactorial, and not well understood. Recent advances in molecular testing are promising. More studies are needed prior to the formal inclusion of molecular markers in the staging system of DTC.
No takes yet. Share an insight, caveat, or question.
Kazaure et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: